Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...

VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modificationIntermediate-dose study arm: enrollment complete Initial immunologic data from low...

CRISPR Therapeutics Announces Collaboration with Massachusetts General Hospital to Research Use of CRISPR/Cas9 in T Cell Cancer Therapies ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 22, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...

Editas Medicine Announces Exclusive License to Advanced CRISPR Genome Editing Technology from Massachusetts General Hospital -- License to Engineered Forms of Cas9 Nuclease Includes High-Fidelity Cas9 and Cas9 PAM Variants -- CAMBRIDGE, Mass., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a...

Massachusetts General Hospital Improves Communication in Its Operating Rooms With Vocera SAN JOSE, Calif., Dec. 09, 2015 (GLOBE NEWSWIRE) -- Vocera Communications (NYSE:VCRA), the leading mobile healthcare communications company, announced today that Massachusetts General Hospital (MGH)...